非小细胞肺癌中的KRAS突变:转化方面,当前疗法和未来研究的挑战
Maria Colombino1, Grazia Palomba1, Milena Casula1
1Unit of Cancer Genetics, Institute of Genetic & Biomedical Research (IRGB), National Research Council (CNR), Traversa La Crucca n. 3, Sassari 07100, Italy.
Critical reviews in oncology/hematology
|September 7, 2025
概括
克拉斯突变驱动非小细胞肺癌 (NSCLC). 新的KRAS抑制剂显示出有希望但面临耐药性;针对KRAS,瘤微环境 (TME) 和免疫逃避的组合疗法对于改善结果至关重要.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症遗传学 癌症遗传学
背景情况:
- KRAS突变是非小细胞肺癌 (NSCLC) 的关键驱动因素.
- 从历史上看,克拉斯一直是一个国家.
- 没有药物可用的无毒药.
- 但特定的KRAS-G12C抑制剂 (索托拉西布,阿达格拉西布) 现在已获得批准.
- 抵抗机制和免疫抑制性瘤微环境 (TME) 限制了目前的治疗方法.
研究的目的:
- 审查NSCLC中的KRAS变化,重点关注分子途径和向疗法.
- 讨论诸如瘤异质性和抵抗机制等挑战.
- 探索涉及KRAS抑制剂,免疫检查点抑制剂 (ICI) 和TME调制的组合策略.
主要方法:
- 在NSCLC中对KRAS突变的文献综述.
- 分析分子通路,抵抗机制和TME.
- 评估当前和新兴的治疗策略.
主要成果:
- 克拉斯-G12C抑制剂提供了新的治疗选择,但受到耐药性的阻碍.
- 瘤微环境 (TME) 和免疫逃避有助于治疗失败.
- 组合疗法正在成为一个有前途的战略.
结论:
- 针对KRAS,以及解决耐药性和TME,对于改善NSCLC结果至关重要.
- 组合疗法具有克服治疗局限性的潜力.
- 对非G12C KRAS突变和新型治疗组合的进一步研究是有必要的.
更多相关视频
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
352
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.6K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer
53.5K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.5K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
The Ras Gene
7.1K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.1K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
